Furthermore, sorafenib treatment increases the number of CD4 + CD25 + FOXP3+ Treg infiltrating HCC and inhibits CXCR4, preventing drug resistance due to the immunosuppressive microenvironment established following sorafenib treatment, suppressing tumor growth. Here, CD4 is linked to hepatocellular carcinoma.